key: cord-0036575-kvcyb3t8 authors: Hong-Wu, Zeng; Jing, Yuan; Wen-Xian, Huang; Hong-Jun, Li; Lu, Pu-Xuan; Xiao-Hua, Le; Hua, Huang; Xiao-Ming, Mao; Lei, Zhou; Ya-Nan, Hu; Hao-Peng, Wang; Qian-Qian, Zhang; Ziling, Sha title: Influenza A (H1N1) date: 2015-07-25 journal: Diagnostic Imaging of Emerging Infectious Diseases DOI: 10.1007/978-94-017-7363-8_4 sha: cb554951f73b9099a0c0007d2956b63596321041 doc_id: 36575 cord_uid: kvcyb3t8 In March 2009, an outbreak of human-infected swine influenza occurred in Mexico, with reports of deaths. Soon afterward, such cases were reported worldwide, namely, a pandemic outbreak. The prevailing disease is then defined as an acute respiratory infectious disease caused by swine-origin influenza A (H1N1) virus, a new variant of influenza virus. Its viral strains contain gene segments of three types of influenza viruses, namely swine influenza virus, avian influenza virus and human influenza virus. And the virus is mainly transmitted among humans via direct and indirect contact or respiratory tract. In March 2009, an outbreak of human-infected swine infl uenza occurred in Mexico, with reports of deaths. Soon afterward, such cases were reported worldwide, namely, a pandemic outbreak. The prevailing disease is then defi ned as an acute respiratory infectious disease caused by swine-origin infl uenza A (H1N1) virus, a new variant of infl uenza virus. Its viral strains contain gene segments of three types of infl uenza viruses, namely swine infl uenza virus, avian infl uenza virus and human infl uenza virus. And the virus is mainly transmitted among humans via direct and indirect contact or respiratory tract. This new virus is originated from pigs. Initially, WHO nominated such infl uenza as "human-infected swine infl uenza." However, such a nomination may cause misunderstandings about intake of pork and pork products. And such a nomination may even involve certain issues about religions and beliefs. Therefore, the infl uenza is known as "North American Infl uenza" by the World Organisation for Animal Health, "New Infl uenza Virus" by the European Union, "Mexican Virus" by South Korea and Israel, and "Mexican fl u" by New Zealand. In China, it was initially nominated as "human-infected swine infl uenza," and "New H1N1 infl uenza" in Taiwan. In order to avoid misleading the public, the WHO declared on 30 April 2009 in Geneva that the nomination of "swine infl uenza" is terminated and the disease is renamed as "Infl uenza A (H1N1)." On 11 June 2009 , the WHO raised the pandemic alert level of infl uenza to Phase 6. By 21 March 2010, according to the WHO offi cial website, the laboratory confi rmed cases of infl uenza A (H1N1) had been reported from more than 213 countries and regions including at least 16,931 deaths. By 7 March 2010, according to data from China, 127,427 confi rmed cases had been reported from 31 provinces in mainland, including 8320 severe and critical cases, and 796 deaths. The death rate of the pandemic of infl uenza A (H1N1) is 0.4-6.77 %, being higher than that from common infl uenza. The main pathogen causing infl uenza is the infl uenza virus, which can be categorized into the family of Orthomyxoviridae and the genus of infl uenza virus. Infl uenza viruses are composed of envelope and segmental single-stranded negative RNA. The virus consists of three parts, namely, from the outside to the inside, the envelope, matrix protein (M protein), and the core. According to matrix protein antigens, genetic characteristics, and virus nucleoprotein particles, the infl uenza viruses can be classifi ed into type A (A), type B (B), and type C (C). Infl uenza A can cause seasonal epidemics in certain regions and may even lead to a worldwide pandemic outbreak. Infl uenza A (H1N1) virus is a single-stranded RNA virus which is categorized into the family of Orthomyxoviridae and the genus of infl uenza A virus. According to different antigenic characteristics of hemagglutinin (HA) and neuraminidase (NA) on the surface of virus, infl uenza A viruses can be classifi ed into several subtypes. HA acts like a key to unlock the door of the host cells for the invading viruses, while NA contributes to destroy the cell receptor, which renders free transmission of the viruses in the body of the host. Both enzymes are highly variant, and the defi ned infl uenza A viruses, so far, are nominated based on different combinations of 16 types of HA (H1-16) and 9 types of NA (N1-9), such as H1N1, H1N2, H5N1, etc. Among all the subtypes, HA 1-3 can cause pandemic of human infl uenza, and H1N1, H1N2, and H3N2 are common and fi xed virus phenotypes causing human infl uenza. In human history, three pandemic outbreaks of infl uenza occurred in 1918, 1957, and 1968 . The prevailing infl uenza virus in the pandemic of 1918 was infl uenza A (H1N1) virus. Due to common existence of most infl uenza A (H1N1) virus strains in pigs, the WHO once nominated the infl uenza as swine infl uenza at the beginning of its outbreak. Typical infl uenza A (H1N1) virus particle is enveloped and spherical whose diameter is 80-120 nm. Many raised glycoproteins (spikes) are radially arranged on the surface of lipid envelope. These spikes are 10-14 nm of erythrocyte hemagglutinin (HA), neuraminidase (NA), and matrix protein M2. Matrix protein (M1) is located inside the envelope of the virus. The nucleocapsids inside the viral particle are spirally symmetrical whose diameter is 10 nm. Such nucleocapsid contains RNA segments and polymerase proteins (PB1, PB2, PA). Certain enzymes (including glycoproteins hemagglutinin and neuraminidase) play a vital role in the entire life cycle of the virus. The genome of infl uenza A (H1N1) virus is approximately 13.6 kb and is composed of eight unequally sized independent RNA segments which separately encode ten kinds of proteins: NA, HA, PA (RNA polymerase subunit PA), PB1 (RNA polymerase subunit PB1), PB2 (RNA polymerase subunit PB2), M (matrix protein, including M1 and M2, encoded by the same RNA segment), NS (nonstructural proteins, including N1 and N2, encoded by the same RNA segment), and NP (nucleoprotein). Infl uenza A (H1N1) virus is composed of three kinds of gene segments from swine infl uenza virus, avian infl uenza virus, and human infl uenza virus, which is a new mutant strain of swine infl uenza virus (SIV). Infl uenza A (H1N1) virus is sensitive to heat and can be inactivated at 56 °C for 30 min. It is also sensitive to ultraviolet rays. But the UV-inactivated swine infl uenza virus can induce multiple reactivation of the virus. Swine infl uenza virus is an enveloped virus and is sensitive to ethanol, iodophor, iodine tincture, chloroform, acetone, and other organic solvents. In human history, pandemic outbreak of infl uenza occurred for several times. It has a high incidence, and populations are generally susceptible to it. Its global infection rate is 5-20 % and its mortality rate is 0.1 %. Within the twentieth century, fi ve pandemic outbreaks of infl uenza occurred in respective years of 1900, 1918, 1957, 1968, and 1977 . The pandemic outbreak of infl uenza A (H1N1) in 1918 in Spain is the most serious, with about 500 million people being infected worldwide and a mortality rate of 2.5 %. In the year of 2009, an outbreak of infl uenza fi rstly occurred in Mexico City. On 18 March 2009, a signifi cant increase of infl uenza-like cases was reported by the local health agency. On 30 March 2009, a 10-year-old boy in California, USA, experienced fever, cough, and vomiting. Two days later, his conditions deteriorated and the boy was sent to an emergency clinic for treatment. One week later, the boy was cured. On 15 April 2009, the CDC of the USA received the clinical specimens of this boy and then defi ned a new swine-origin infl uenza virus, infl uenza A (H1N1) virus. The WHO and the CDC indicated that the infl uenza cases in Mexico and the USA were infected by the same strain of H1N1 subtype of swine infl uenza virus. After large-scale prevalence of a new infl uenza virus in human being, persons with a history of infection or vaccination can acquire certain resistance to such virus. When such infl uenza virus prevails again, its transmissibility and infectivity can be greatly reduced. The infl uenza A (H1N1) virus has no exception. Its gradually weakened transmissibility and infectivity have changed infl uenza A (H1N1) into a seasonal fl u, and the virus is currently the dominant strain of infl uenza. The prevalence of infl uenza A (H1N1) is currently characterized by decreased epidemic intensity and range as well as low incidence rate of severe cases, which have been shown by data from the prevalence of infl uenza A (H1N1) in 2013. Infl uenza A (H1N1) is mainly transmitted via respiratory tract. Its transmission route is various and its transmission is rapid. The virus can survive and spread in densely populated places with poor ventilation and spread widely along with fl ow of population to cause prevalence of the disease. The main source of infection is patients with infl uenza A (H1N1) and infected asymptomatic person. Although the infl uenza A (H1N1) virus has been found in the body of pigs, no evidence has been found to prove that the animal is the source of infection. The infective stage of the patient with infl uenza A (H1N1) is the period from 1 day prior to the onset of symptoms to day 7 after the onset or to 24 h after the absence of symptoms (the longer one should be defi ned as the infective stage). The infective stage may be longer in patients of young children, patients with compromised immunity, and patients critically/seriously ill. In some cases, the virus-carrying persons experience no onset of symptoms but can still infect others. The virus is mainly transmitted via respiratory tract after inhalation of virus-containing droplets or aerosols from sneezing or coughing of infected persons. The virus can also be transmitted via direct or indirect contacts to the mucosa of oral cavity, nose, and eyes. Contacts to respiratory secretions, body fl uids, and contaminated utensils of the patients can also cause infection. In addition, the fecal-oral transmission should be taken into account, because many patients experience diarrhea, and fecal detoxifi cation is possible. Humans cannot be infected by infl uenza A (H1N1) virus via contacts to pork or intake of pork products. On 12 April 2009, a Canadian farm worker feeding pigs experienced some infl uenza symptoms after traveling Mexico. He was then diagnosed with infl uenza A (H1N1). The pigs in this farm began to have infl uenza symptoms since 24 April 2009. On 2 May 2009, Canadian government offi cially announced that about 220 pigs in this farm were infected by infl uenza A (H1N1) virus. The swine infection indicated that human-infected swine infl uenza can be transmitted to pigs. Populations are generally susceptible to infl uenza A (H1N1), with no specifi c immunity. Youngsters aged 9-19 years have a high incidence, with clustering cases in affected school within short period of time. The following are the high-risk populations of infl uenza A (H1N1), and these populations are likely to develop into severe cases after onset of infl uenza symptoms. Therefore, these populations should be highly concerned. • Pregnancies; • Obese people (BMI ≥40 means a high risk, BMI between 30 and 39 means a risk factor); • Children under the age of 5 years (young children patients aged under 2 years are more likely to develop serious complications); • Elderly people >65 years old; • The patients with the following underlying diseases or conditions: chronic respiratory disease, cardiovascular disease (except hypertension), kidney disease, liver disease, hematological disease, neurological and neuromus-cular disease, metabolic and endocrine system disease, and immune suppression (including those with compromised immunity due to use of immunosuppressor or HIV infection); and the patients aged under 19 years with long-term intake of aspirin. The abovementioned populations with infl uenza-like symptoms should receive viral nucleic acid test for infl uenza A (H1N1) and other necessary examinations as early as possible. The Infl uenza A (H1N1) can be complicated by multiple organ dysfunction (MODS). Its mechanism is as the following: (1) the infl uenza A (H1N1) virus can invade the lungs to cause severe pulmonary infl ammation. And in some cases, the condition may rapidly progress into acute respiratory distress syndrome (ARDS). (2) The patients with infl uenza A (H1N1) sustain different degrees of hypoxemia, which enhances anaerobic metabolism of tissue cells and reduces the production of ATP and cAMP. Therefore, the energy metabolism in organs is disturbed. Hypoxia can also lead to decreased cardiac output, insuffi cient circulating blood volume and reduced organ or tissue perfusion. (3) Secondary infection may occur. The infl uenza A (H1N1) virus can cause acute respiratory infectious disease, which may progress into interstitial pneumonia in some severe cases, with a mortality rate of about 0.1-0.2 %. The pathological changes of severe infl uenza A (H1N1) mainly include severe pulmonary disease, multiple organ dysfunction, and secondary infection. The main causes of death include (1) progressive respiratory failure induced by diffuse alveolar lesion; (2) the complication of multiple organ dysfunction including the liver, kidney, and heart; and (3) secondary infection. The pathological changes noticeable by naked eyes include: increased volume of both lungs with increased weight but decreased air content, consolidation of both lungs, and dark reddish lungs with fi brinous exudates on their surfaces. Under a light microscope, diffuse alveolar lesion can be observed at both lungs, which is mainly acute diffuse exudates with presence of pulmonary tissue necrosis ( Fig. 4.1 ) . The alveolar cavity is demonstrated with edema and/or fi brinous and infl ammatory exudates ( Fig. 4 .2 ), with formation of pulmonary hyaline membrane. In some alveolar cavities, hemorrhages can be observed, with hyperplasia of type II alveolar epithelial cells. Neither megakaryocytes nor inclusions in nucleus or cytoplasm can be observed. Some alveolar septa are demonstrated to be slightly widened, with vascular dilatation, congestion, and necrosis ( Fig. 4. 3 ), as well as thrombus in some cases. Pulmonary interstitial fi brosis is present. Virus particles can be observed both within and out of the infected cells in alveolar cavity of pulmonary tissue. The virus is round or oval in shape with a diameter of averagely about 88 nm, and some viruses are surrounded by spikelike structure in a length of about 12 nm. The heart is slightly heavier. Under a light microscope, myocardial cells are degenerated, with myocardial breakage, myocardial interstitial edema, infi ltration of small quantity or no infl ammatory cells, and degeneration of atrial ganglion cells (Figs. 4.4 , 4.5 , and 4.6 ). The liver can be observed with congestion, focal hepatocytic swelling and fatty degeneration, and infi ltration of small quantity mononuclear cells at the portal area. Erythrocytophagy can be observed ( Fig. 4.7 ) . The kidney can be observed with congestion. Under a light microscope examination, glomerular congestion is observed, with edema of renal tubular epithelial cells but no microthrombus and renal tubular necrosis. The pathological changes include cerebral edema and congestion, with visible hemorrhagic focus, focal liquefactive necrosis at the capsule, and neuronal degeneration ( Fig. 4.8 ). Hemophagocytic phenomenon can be observed at some lymph nodes and bone marrow (Fig. 4.9 ). The spleen can be observed with reduced lymphocytes, histiocytosis, and hemophagocytic phenomenon (Fig. 4.10 ). The patients with infl uenza A (H1N1) can develop secondary bacterial and fungal infections. The pathogenic bacteria are mainly gram-positive coccus. The nucleoprotein antigen of infl uenza A (HIN1) virus is located at the nucleus and cytoplasm of infected cells, including epithelial cells at airway, submucosal glands of airway, and detached and lining epithelial cells at alveolus. In addition, the antigen can also be found at the hyaline membrane and rarely vascular endothelial cells. Double labeling has revealed that the target cell of viral infection is pulmonary epithelial cells, predominantly type II alveolar epithelial cells (co-labeled with cytokeratin) and occasionally macrophages. No viral antigen of infl uenza A (H1N1) virus is immunohistochemically detected in nonrespiratory tissue. By RT-PCR, the nonrespiratory tissue is also detected negative for infl uenza A (H1N1) virus. Infl uenza A (H1N1) is a self-limited respiratory disease. Its clinical manifestations resemble to those of seasonal infl uenza, being mild in most patients. However, the patients from high-risk populations are more likely to develop into severe cases and even death. The incubation period of infl uenza A (H1N1) generally lasts for 1-7 days, mostly 1-3 days, which is longer than that of common infl uenza and avian infl uenza. The patient usually experiences infl uenza-like symptoms, including fever (axillary temperature ≥37.5 °C), sore throat, runny nose, nasal congestion, cough, expectoration, headache, general soreness, and fatigue. In some cases, the patients experience vomiting and/or diarrhea. In rare cases, the patients only experience mild upper respiratory symptoms with no occurrence of fever. The signs mainly include pharyngeal congestion and swollen tonsils. Total WBC count is commonly within or lower than normal range. In some severe pediatric cases, the total WBC count may increase. The common cases commonly show normal or lower WBC count, while the severe cases show normal or increased peripheral WBC count. The increase of WBC count in severe cases may be related to complicated infections. It should be paid close attention that, compared to common cases, the severe cases have obviously decreased percentage and absolute count of peripheral blood lymphocytes. Peripheral blood lymphocyte count <800 cells/ml is a high-risk factor for patient with infl uenza A (H1N1) to develop respiratory failure. The decrease of both percentage and absolute count of peripheral lymphocytes is an indicator for early prediction. The blood biochemistry for liver function is commonly normal in most patients. Only in rare cases, the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) can be tested with increase. Myocardial enzyme of creatine kinase (CK) exists in the cytoplasm and mitochondria of skeletal muscle, heart, brain, and other tissues, which is an important kinase directly related to intracellular energy transformation, muscle contraction, and ATP regeneration. Its level increases in the cases with myocardial damage. The blood glucose level in both critical cases and death cases is higher than that in severe cases, which may be related to responses of host to stress. In some cases, hypokalemia or hypocalcemia occurs. Relevant studies have demonstrated that hypocalcemia is an important indicator predicting poor prognosis of infl uenza A (H1N1). The infection of infl uenza A (H1N1) virus can cause allergic reaction. In critical cases, the serum cytokine significantly increases, with increased permeability of pulmonary and cerebral vascular vessels, to cause respiratory failure and pulmonary edema. Therefore, the test for serum cytokines plays an important role in assessing conditions of infl uenza A (H1N1) and guiding clinical prevention and treatment. The test for viral nucleic acid is currently the main diagnostic examination for infl uenza A (H1N1). The respiratory specimens, including throat swabs, nasal swabs, nasopharyngeal or tracheal extracts, and sputum, are tested by using RT-PCR (more favorably real-time RT-PCR). The cases of infl uenza A (H1N1) show positive results. In the cases of infl uenza A (H1N1), the pathogenic virus can be isolated from respiratory specimens. In the cases with infl uenza A (H1N1) complicated by viral pneumonia, the virus can also be isolated from the lung tissue. In the cases of infl uenza A (H1N1), dynamic tests of double sera specimens show at least four times increase of the neu-tralizing antibody specifi c to infl uenza A (H1N1) virus. The result may facilitate to defi ne the diagnosis and the retrospective diagnosis. The patients with infl uenza A (H1N1) experience different degrees of fever, cough, expectoration, chest distress, shortness of breath, fatigue, headache, and myalgia, all of which are collectively referred to as the fl ulike symptoms. Although the infl uenza A (H1N1) virus is a new mutant of infl uenza virus, the symptoms of infected patients can be hardly distinguished from infections of respiratory syncytial virus, parainfl uenza virus, rhinovirus, adenovirus, Coronavirus , and Legionella pneumophila . Therefore, the diagnosis cannot be defi ned based only on the symptoms, but needs to combine fi ndings of specifi c laboratory tests, such as serological test, viral nucleic acid test, and pathogen isolation. The case with the following ONE condition can be diagnosed as a suspected case: 1. The patient has a history of close contact to patient suspectively or defi nitively diagnosed with infl uenza A (H1N1) at its infectious stage within 7 days prior to the onset of infl uenza-like symptoms. Close contact refers to attending to patients with infl uenza A (H1N1) in its infectious stage with no effective protection; living together with the patient and exposure to the same environment with the patient; and direct contact to the airway secretions, body fl uids, and other contaminated utensils from the patient. 2. The patient has a history of visiting the country or region with epidemic of infl uenza A (H1N1) (continuous spread of virus from person to person and community-based prevalence and outbreak) within 7 days prior to the onset of infl uenza-like symptoms. 3. The patient experiences infl uenza-like symptoms and shows positive to test for infl uenza A (H1N1) virus, but infection of previous infl uenza virus subtypes has not been further excluded. The cases with ONE of the above three conditions should be etiologically tested for infl uenza A (H1N1), if possible. The clinical diagnosis should be made based only on the following condition. During the same epidemic event of infl uenza A (H1N1), the patient with infl uenza-like symptoms has not defi nitively diagnosed by laboratory test but has been excluded from other diseases with infl uenza-like clinical manifestations. Such patients can be clinically diagnosed as infl uenza A (H1N1). Outbreak of infl uenza A (H1N1) refers to abnormally increased occurrence of infl uenza-like disease in one region or unit within a short period of time, and the disease is defi ned to be infl uenza A (H1N1) by laboratory tests. If possible, the clinically diagnosed patients should receive etiological examination. The cases with infl uenza-like symptoms and at least ONE of the following laboratory fi ndings can be defi nitively diagnosed as infl uenza A (H1N1). tested positive by real-time RT-PCR or RT-PCR. 2. The serum level of neutralizing antibody specifi c to infl uenza A (H1N1) is tested with at least four times increase. The severe cases can be defi ned based on ONE of the following conditions. 1. Persistent fever lasting from more than 3 days, accompanied by severe cough, purulent and/or bloody sputum, or chest pain 2. Rapid respiratory rate, dyspnea, cyanotic lips 3. Consciousness changes, including delayed response, drowsiness, restlessness, and convulsions 4. Severe vomiting and diarrhea, dehydration 5. Radiological fi ndings of pneumonia-like signs 6. Rapid increases of myocardial enzyme levels, such as creatine kinase (CK), creatine kinase M isoenzyme (CK-MB), etc. 7. Obviously aggravated previous underlying disease The critical cases can be defi ned based on ONE of the following conditions: Infl uenza A (H1N1) is commonly complicated by diseases of respiratory and central nervous system. The selection of radiological modalities is mainly based on the two systems. The suspected cases should receive upright posterior-anterior chest X-ray. For the severe cases of inability going to the radiology department, a bedside chest X-ray can be performed to assess the condition at a posture of sitting or lying. If possible, a special stand for upright chest X-ray or seated chest X-ray can be used. The children patients capable of standing should receive upright chest X-ray. For patients unable of standing due to severe conditions, seated chest X-ray is preferred. The indications for bedside radiological examination are as the following: 1. Persistent fever lasting for at least 3 days 2. Cough with/without expectoration 3. Positive fi nding in viral nucleic acid test for infl uenza A (H1N1) 4. Signs of pulmonary infl ammation by the fi rst radiological examination When a patient with suspected diagnosis of infl uenza A (H1N1) experiences above conditions 1, 2, and 4, a bedside radiological examination should be performed. If a patient with suspected diagnosis of infl uenza A (H1N1) experienced the above condition 3, the bedside radiological examination is NOT necessary. The patients, radiological technicians, and other healthcare workers should be protected against radiohazards. Data revealed that the average radiation dose at the chest surface of the patient by a bedside X-ray machine is 1.45 mGy/time, and its maximum dose is 3.39 mGy/time. The radiation dose by other digital chest X-ray machines is about (0.36 ± 0.05) mGy/time. The radiation dose of bedside X-ray machine is signifi cantly different from that of other digital chest X-ray machine. Before entering into the isolation ward, the radiological technicians should receive training for knowledge and skills about disinfection and isolation. The procedures should be constantly improved. The patients with infl uenza A (H1N1) experience rapid changes of lung lesions. Therefore, reexamination of chest X-ray within a short period of time facilitates to assess the condition. During the convalescent stage, chest X-ray should be regularly performed to assess the absorption of lesions and the residual lesions. In recent years, based on the application of new detectors and new algorithm for image reconstruction, the low-dose CT scan can be routinely performed. CT scans are favorable in detecting chest lesions and their characteristics, which can be applied for patients whose diagnosis cannot be defi ned by chest X-ray. CT scan can display occult lesions posterior to the heart shadow and at the posterior costophrenic angle, which can effectively avoid misdiagnosis and increase the detection rate of the lesions. MRI has the absolute advantage in displaying lesions at the central nervous system due to its capabilities in multiparameter imaging, 3D imaging, and functional imaging. Therefore, MRI is the choice of radiological modalities for the examination of central nervous system. CT scan is applied only when MRI is inapplicable. Influenza A (H1N1) may be complicated by aseptic meningitis, encephalitis, and acute necrotizing encephalopathy. MRI should be performed with conventional plain imaging and contrast imaging. FLAIR and DWI sequences should be additionally performed during contrast imaging to more favorably display meningeal lesions. When MRI is performed for young children, some measures should be used to keep him/her warm and limit his/ her movement. In addition, due to the loud noise generated during MRI, a pair of soundproof earplugs should be plugged into the ears of pediatric patient so as to avoid awakening the child and to prevent hearing damage. For the pediatric patient with poor compliance, oral/enema use of chloral hydrate can be administered to calm down the child prior to MRI. Radiological Demonstration Infl uenza A (H1N1) is a new respiratory infectious disease. And respiratory complications, such as pneumonia and pulmonary edema, are important and common. Death may occur in critical cases due to respiratory failure. For the patients with infl uenza A (H1N1), abnormalities displayed by chest radiological examinations are always in inpatients and severely ill patients receiving intensive care. The common complications mainly include pneumonia, pleural effusion, pulmonary edema, pneumothorax, and mediastinal emphysema. Infl uenza A (H1N1) is commonly complicated by pneumonia, with multiple lesions. Its radiological demonstrations share some commonalities with common pneumonia, such as exudative lesions, lung consolidation, pulmonary edema, and pleural effusion. Meanwhile, pneumonia complicating infl uenza A (H1N1) is characterized by commonly bilateral lesions as well as rapid change and exacerbation of the lesions and its range. The most common radiological demonstrations are groundglass opacities and consolidation opacities at lungs. The two types of opacities may be separately or jointly present, commonly with reticular and nodular opacities. In rare cases, the lesions are demonstrated as consolidation opacities at pulmonary segments or lobes with air bronchogram, accompanied by or no segmental atelectasis. The lesions are commonly found at bilateral lower lung fi elds, which are focal, multiple, or diffusely distributed. Intrapulmonary nodular opacities, interlobular septal thickening, peribronchial patchy opacities, and pleural effusion are rarely found radiological signs (Fig. 4.11 ) . 1. The common chest CT scan demonstrations are unilateral or bilateral ground-glass opacities, with or without singular consolidation or multiple fused consolidations. 2. The intrapulmonary lesions have lobular, segmental, or lobar distribution and often manifest as light thin small fl aky or multiple patchy integrated lesions. By HRCT, the ground-glass opacities are commonly distributed at the peribronchovascular or subpleural region. The lesions are mostly located at both lower lung lobes or multiple lobes and segments of both lungs. In severe cases, the lesions are always shown as multifocal and integrated consolidation at both lungs with air bronchogram. Otherwise, the severe cases can be demonstrated with atelectasis. 3. The lung lesions can be completely absorbed within a short period of time, generally within 7-15 days. The absorption of lesions commonly lags behind the improvement of clinical conditions. At the early stage of the disease, ground-glass opacities may be integrated as multiple scattering consolidation opacities. Some of the consolidations are not integrated at the onset, but will be integrated within the following several days. The multiple scattering patchy opacities can change into light thin small fl aky opacities and gradually disappear. 4 . In some cases, the above lesions are accompanied by small quantity of pleural effusion and mediastinal lymphadenectasis ( Fig. 4.12 ) . Pneumonia demonstrated as fl aky opacities confi ned within the lungs is defi ned as mild. That demonstrated as intrapulmonary fl aky opacities with more than two lung lobes involved are defi ned as moderate. And that demonstrated as intrapulmonary lesions with at least three lung lobes involved are defi ned as severe. For the patients with mild to moderate pneumonia, pulmonary infl ammation can be gradually absorbed after the use of effective therapy. The radiological demonstrations are not necessarily According to a study of viral load in 20 patients with infl uenza A (H1N1) whose chest CT scans were normal, the minimum viral load is 2.4 copies/ml, while the maximum viral load is 5.5 copies/ml, with a mean of 4.2 copies/ml. In this study, the dynamic viral load was also measured in 21 patients with infl uenza A (H1N1) whose chest CT scans demonstrated pneumonia. The average viral load is 7.7 copies/ml. The viral load has statistical difference ( P < 0.05) between the group without pneumonia and the group with pneumonia. The fi ndings primarily indicated that pneumonia does not occur to complicate infl uenza A (H1N1) in the cases with a viral load lower than 5.5 copies/ ml (Fig. 4.13 ) . The same study also demonstrated that the severity of pneumonia complicating infl uenza A (H1N1), with an indicator of CT semiquantitative score, is not signifi cantly related to the viral load. In general, the level of viral load indicates the degree of infection. However, by dynamic chest CT scoring (Radiology, 2003) in 21 cases of infl uenza A (H1N1) complicated by pneumonia and their viral load measures, it has been found that the severity (chest CT semiquantitative score) of pneumonia complicating infl uenza A (H1N1) is not related to the viral load, because no statistically signifi cant difference was found ( P > 0.05). That is to say, a high level of viral load does not necessarily indicate severe lesions of pneumonia. 1. Location of lesions: commonly at the middle (lingular segment) and lower lobes of both lungs. 2. Morphology of lesions: mostly large or small fl aky opacities. 3. Density of lesions: mainly high-density consolidation opacities, light thin opacities, or ground-glass opacities. 4. The lesions are mostly accompanied by unilateral/bilateral pleurisy or pleural effusion or other changes. The pathomechanism underlying pleurisy remains unknown, which may be related to hypoalbuminemia, direct effects of viruses, or endocrine factors. 5. After clinical treatment, the ground-glass opacities at the lungs can be completely absorbed within a short period of time; large high-density consolidation opacities can be obviously absorbed; the residual lesions in the advanced stage can be absorbed slowly (Fig. 4.14 ) . It may develop due to pulmonary edema or pneumonia with the pleura involved. In severe pediatric cases of infl uenza A (H1N1), the incidence of pneumonia complicated by pleural effusion is relatively higher. By CT scan, the lesions are mostly located at the peripheral lung with the subpleura involved and pleurisy may be demonstrated. Pneumothorax and mediastinal emphysema may occur in patients with underlying asthma, and their occurrence is possibly a result of increased intrapulmonary pressure due to shortness of breath caused by influenza A (H1N1) virus. The risk of developing pneumothorax and mediastinal emphysema in severe cases receiving intensive care can be increased due to mechanical ventilation (Figs. 4.15 and 4.16 ). As a result of infl ammatory responses, mediastinal and axillary lymphadenectasis occurs, with no necrosis and integration. Plastic bronchitis has an extremely rare occurrence whose diagnosis can be defi ned by bronchoscopy based on suction of branch-like bronchial casts. Pathologically, it is fi brinous exudation or fi brinous exudation with necrosis and may be accompanied by infi ltration of neutrophils, eosinophils, and lymphocytes. Chest X-ray demonstrates some indirect signs, like lung consolidation and atelectasis. Airway reconstruction after CT scan shows higher-density opacities in the cavity (Fig. 4.17 ). The critical and severe pediatric cases of infl uenza A (H1N1) with respiratory complications are radiologically characterized by multiple patchy ground-glass opacities and consolidation opacities at both lungs, high incidence of pleural effusion, the more common complications of pneumonia, and pulmonary cryptococcal infection (Fig. 4.18 ). Some critical and severe pediatric patients with infl uenza A (H1N1) develop diseases of the central nervous system. The common complications of the central nervous system include infl uenza-related encephalopathy, aseptic meningitis, encephalitis, acute necrotizing encephalopathy, and secondary intracranial fungal infection. Infl uenza-related encephalopathy has symptoms of the central nervous system and abnormalities on EEG. However, no abnormality can be found by CSF and cranial radiology. The disease is often clinically diagnosed and radiological examination is performed to exclude other possible complications. MRI shows bilaterally symmetrical lesions at the deep white matter and basal ganglia (including the thalamus and brainstem tegmentum) of cerebral hemisphere. Aseptic meningitis is often clinically diagnosed Plain MRI scan is often negative, and contrast MRI occasionally shows meningeal enhancement at both cerebrum and cerebellum that is nonspecifi c. The pediatric patients with aseptic meningitis commonly have a good prognosis (Fig. 4.19 ). Both have extremely rare occurrence. The lesions may be located at the frontal lobe, parietal lobe, occipital lobe, and other parts, which may involve cortical and subcortical tissues, corpus callosum, and the thalamus. The area with lesions is demonstrated with low density by CT scan, long T1 and long T2 signals by MRI, and slight or no enhancement by contrast imaging. ( c ) Contrast imaging demonstrated obvious enhancement of the cerebellar meninges The radiological manifestations are characteristic, showing multifocal and symmetric brain lesions that are characterized by symmetric involvement of bilateral thalami. The internal capsule, lenticular nucleus, brain stem, and cerebral and cerebellar medullary substances can also be involved. The area with lesions is demonstrated with low density by CT scan, long T1 and long T2 signals by MRI, and high signals by FLAIR. By DWI, signals from the area with lesions are special, with centrally low signal and peripherally high signal of the bilateral thalami. ADC shows slightly high signal at the center that is surrounded by ring-shaped low signal (Fig. 4.20 ) . Secondary intracranial fungal infection occurs in the pediatric patients mainly due to immunosuppression and long-term use of antibiotics or glucocorticoid. It may be mucor or cryptococcal infection, which is radiologically demonstrated as common fungal infection. MRI demonstrates fungal meningitis as obvious meningeal enhancement and fungal granulomas as round-like slightly long T1 and long T2 signals with marginal enhancement by contrast imaging (Fig. 4.21 ) . Pneumonia and respiratory failure from swine-origin infl uenza A (H1N1) in Mexico Recent studies on outbreak of infl uenza A (HINl) in 2009 Relationship between respiratory viral load and lung lesion severity: a study in 24 cases of pandemic H1N1 2009 infl uenza A pneumonia Pandemic potential of a strain of infl uenza A (H1N1): early fi ndings Epidemiology and clinical manifestations of defi nitively diagnosed cases of infl uenza A (HINl) in Shenzhen Changes of immune function in pediatric patients with infl uenza A (H1N1) in 2009 Histopathological study on death cases of critical and severe infl uenza A (H1N1) Clinical manifestations, viral load and viral detoxifi cation duration in patients with mild or severe infl uenza A (HINI) The effect of Th17 lymphocytes on clearance of infl uenza A (H1N1) virus Cellular immunity of patients with infl uenza A (HlNl) complicated by pneumonia pandemic infl uenza A (H1N1) pathology and pathogenesis of 100 fatal cases in the United States Severe respiratory disease concurrent with the circulation of H1N1 infl uenza Pathogenesis and transmission of triple-reassortant swine H1N1 infl uenza viruses isolated before the 2009 H1N1 pandemic Physiological numbers of CD4+ T cells generate weak recall responses following infl uenza virus challenge Emergence of a novel swineorigin infl uenza A (H1N1) virus in humans Infection and death from infl uenza A H1N1 virus in Mexico: a retrospective analysis Actin and RIG-1/MAVS signaling components translocate to mitochondria upon infl uenza A virus infection of human primary macrophages Pandemic (H1N1) 2009 infl uenza A (H1N1) infl uenza virus pandemic: a review Pandemic H1N1 infl uenza virus causes a stronger infl ammatory response than seasonal H1N1 infl uenza virus in ferrets Pathogenesis of pandemic infl uenza A (H1N1) and triple-reassortant swine infl uenza A (H1) viruses in mice Predictors and outcomes of respiratory failure among hospitalized pneumonia patients with 2009 H1N1 infl uenza in Taiwan Generation and characterization of recombinant pandemic infl uenza A (H1N1) viruses resistant to neuraminidase inhibitors Adverse drug reaction profi le of oseltamivir in children Detoxifi cation and antiviral therapy in patients with infl uenza A (H1NI) Risk factors for severe illness with 2009 pandemic infl uenza A (H1N1) virus infection in China Pediatric hospitalizations associated with 2009 pandemic infl uenza A (H1N1) in Argentina Children hospitalized with 2009 novel infl uenza A (H1N1) in California Pathogenesis and transmission of triple-reassortant swine H1N1 infl uenza viruses isolated before the 2009 H1N1 pandemic A (H1N1) infl uenza virus pandemic: a review Reduction of natural killer but not effector CD8 T lymphocytes in three consecutive cases of severe/ lethal H1N1/09 infl uenza A virus infection Clinical and radiological manifestations in pediatric patients with acute necrotizing encephalopathy Emergence of a Novel Swine-origin Infl uenza A (H1N1) Virus in Humans Semi-quantitative scoring of chest CT scan and its relationship with viral load in patients with infl uenza A (H1N1) complicated by pneumonia Chest CT fi ndings and their dynamic changes in patients with infl uenza A (H1N1) complicated by pneumonia Paediatric mortality related to pandemic infl uenza A H1N1 infection in England: an observational population-based study Swine-origin infl uenza a (H1N1) viral infection in children: initial chest radiographic fi ndings Viral load in patients with infl uenza A (H1N1) and its relationship with chest CT fi ndings